Mediphage Bioceuticals
Mediphage Bioceuticals is a Toronto-based private biotech developing msDNA, a proprietary linear DNA vector platform produced via E. coli fermentation, serving pharmaceutical and biotech partners in gene therapy, gene editing, vaccines, and viral vector manufacturing.
- Company typePrivate
- Founded2019
- HeadquartersToronto, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mediphage Bioceuticals does
Mediphage Bioceuticals, Inc. is a Toronto-based private biotechnology company developing a proprietary DNA delivery platform called msDNA (ministring DNA), a linear covalently closed DNA vector produced via an established in vivo E. coli fermentation process. The company's technology addresses quality, safety, and dosing limitations of conventional circular plasmids, in vitro enzymatically produced minivectors, and viral vectors used in gene therapy, gene editing, and vaccine manufacturing. msDNA incorporates proprietary Super Sequences (SSeq) to enhance cellular trafficking and nuclear uptake, and an in-built safety switch designed to prevent oncogenic chromosomal integration, with disclosed data showing 80- to 3,000-fold fewer loss-of-function mutations than competing enzymatic DNA synthesis methods.
The company operates an internal therapeutic pipeline targeting Hemophilia A, Stargardt Disease, and an undisclosed CNS disorder, while also offering msDNA as a premium starting material and drug substance to external pharmaceutical and biotechnology partners. Mediphage generates revenue through technology licensing and option agreements, direct sale of msDNA as drug substance for gene addition, in vivo gene editing, and DNA vaccines, and as a starting material for ex vivo cell therapy and mRNA, lentiviral, and rAAV vector manufacturing. Strategic partnerships include an option agreement with a multinational pharmaceutical company (January 2023), the Ginkgo Bioworks Technology Network (February 2024), CCRM Enterprises (December 2021), and JLABS Toronto accelerator residency.
The company is privately held, headquartered at MaRS West Tower in Toronto, and has raised capital through a pre-seed round (July 2019), a CAD $215K Mitacs grant (June 2020), a CCRM Enterprises investment (December 2021), and a seed round (February 2024). Leadership includes CEO Alvaro Amorrortu (appointed October 2020), CTO Dr. Nafiseh Nafissi (promoted September 2024 from VP R&D), and COO Lee Bowman, supported by a scientific advisory board with representation from Memorial Sloan Kettering, Takeda Pharmaceuticals, and Queen's University.
Mediphage Bioceuticals firmographics
Firmographics- Name
- Mediphage Bioceuticals
- Legal name
- Mediphage Bioceuticals, Inc.
- Website
- https://mediphage.ca
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mediphage Bioceuticals is a Toronto-based private biotech developing msDNA, a proprietary linear DNA vector platform produced via E. coli fermentation, serving pharmaceutical and biotech partners in gene therapy, gene editing, vaccines, and viral vector manufacturing.
- Ownership category
- akta.pro rank
Mediphage Bioceuticals industry classification
Industry- Product category
- Genetic Medicine / Gene Therapy Technology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
- akta.pro secondary industries
- Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where Mediphage Bioceuticals is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Mediphage Bioceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Technology Licensing and Partnership Agreements: Mediphage generates revenue through licensing its msDNA technology platform to pharmaceutical and biotech partners. The company engages in option agreements and joint feasibility studies with partners evaluating ministring DNA for therapeutic solutions.
- DNA Product Sales: Sale of high-quality msDNA as a premium starting material for ex vivo cell therapy applications and for the manufacture of mRNA, lentiviral, and rAAV vectors. Also sold as drug substance for gene addition, in vivo gene editing, and DNA vaccines.
- Strategic Co-development Revenue: Revenue from collaborative development arrangements including joint feasibility studies and co-development partnerships in non-viral gene therapy, gene editing, and vaccine development.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Mediphage Bioceuticals product offering
Product offeringCore offering
Mediphage Bioceuticals develops and manufactures msDNA™ (ministring DNA), a linear covalently closed DNA vector produced via in vivo E. coli fermentation, used as drug substance for gene addition, in vivo gene editing, and DNA vaccines, and as premium starting material for ex vivo cell therapy and mRNA, lentiviral, and rAAV vector manufacturing. The company also maintains an internal therapeutic pipeline targeting Hemophilia A, Stargardt Disease, and an undisclosed CNS disorder.
Product overview
Mediphage Bioceuticals offers a single unified product platform centered on its msDNA™ (ministring DNA) technology. This proprietary plasmid technology produces linear DNA vectors via an in vivo E. coli fermentation process, differentiating from conventional circular plasmids and enzymatic in vitro DNA synthesis methods. The platform is designed as a versatile starting material and drug substance for various genetic medicine applications including gene therapy, gene editing, DNA vaccines, and viral vector manufacturing. The company's therapeutic pipeline leverages this platform to develop non-viral gene therapies for Hemophilia A, Stargardt Disease, and an undisclosed CNS disorder.
Differentiator
Problem solved
Functional benefit
Products and services
- msDNA™ (ministring DNA) Platform Proprietary linear covalently closed DNA vector produced via E. coli fermentation with high fidelity, low immunogenicity, and reduced insertional mutagenesis risk. Functions as drug substance for gene therapy, gene editing, and DNA vaccines, and as starting material for ex vivo cell therapy and viral vector manufacturing. Customizable for genetic payloads up to 20-25 kb.
Quantifiable outcome
- 80- to 3,000-fold fewer loss-of-function mutations compared to in vitro enzymatic DNA replication methods
- +2 more outcomes
Companies that use Mediphage Bioceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
Mediphage Bioceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Mediphage Bioceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major and minor.
- Ginkgo BioworkscoreMediphage is an inaugural partner of the Ginkgo Technology Network, providing an integrated R&D experience with capabilities from over 25 inaugural partners. This partnership positions Mediphage within Ginkgo's extensive biomanufacturing and technology ecosystem.
- Multinational Big PharmamajorMediphage signed an option agreement with a multinational pharmaceutical company for evaluation and potential development using the msDNA technology platform.
- ArdracoreMediphage-led project in collaboration with Ardra received NGen funding to support Canada's growing biomanufacturing sector. This collaborative project advances manufacturing capabilities in the genetic medicine space.
- JLABS (Johnson & Johnson Innovation)coreMediphage operates out of the JLABS accelerator in Toronto, Canada, leveraging the incubator's infrastructure and ecosystem support for biotech startups developing genetic medicines.
- Lambton CollegeminorResearch partner collaborating on optimization of fermentation and purification processes. Lambton College awarded Mediphage the Research Partner Award of Excellence for 2021.
- University of WaterloominorAcademic research partner with collaboration on vaccine technology development and broader genetic medicine research initiatives.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
Mediphage Bioceuticals competitors and assessment
Company assessmentDirect peers
- Aldevron: Major plasmid DNA manufacturer and CDMO serving gene therapy and vaccine developers (now part of Danaher). Directly comparable as a high-quality plasmid DNA supplier to the same pharma/biotech customer base that Mediphage targets with msDNA.
- Touchlight Genetics: UK-based developer of doggybone DNA (dbDNA), a linear, closed, enzymatic DNA vector for genetic medicine applications. Most direct technology comparable to Mediphage's msDNA, competing head-to-head as a backbone-free linear DNA platform for gene therapy, mRNA production, and viral vector manufacturing.
- VGXI: Specialized plasmid DNA contract manufacturer for gene therapy and DNA vaccine developers. Closely comparable to Mediphage on the DNA CDMO/starting material business model for cell and gene therapy manufacturers.
- GenScript: Global life sciences services company with substantial DNA synthesis and plasmid/gene synthesis manufacturing capabilities serving pharma and biotech. Comparable on the DNA manufacturing/services business model Mediphage is pursuing with msDNA.
- Eurofins Genomics: Large-scale DNA synthesis, gene synthesis, and plasmid manufacturing services provider. Operates as a direct competitor to Mediphage in the high-quality DNA starting material and synthetic gene services market for pharma/biotech customers.
Broad incumbents
- Lonza: Global CDMO leader with extensive cell and gene therapy manufacturing services including viral vector and nucleic acid capabilities. Competes with Mediphage as an incumbent supplier to gene therapy developers but at much broader portfolio scale.
- Catalent: Large CDMO with established gene therapy, plasmid DNA, and viral vector manufacturing capabilities. Comparable as a broader incumbent in the gene therapy supply chain where Mediphage is positioning msDNA as a starting material.
- Charles River Laboratories: Major CDMO and life sciences services provider with gene therapy and nucleic acid manufacturing offerings. Competes as a broader-scale incumbent serving the same gene therapy developer customers that Mediphage targets.
Emerging players
- Intravacc: Dutch vaccine technology development and CDMO organization with expertise in viral vector, conjugate, and DNA vaccine platforms. Comparable on the vaccine technology platform side of Mediphage's application footprint.
Others
- Codexis: Engineered enzyme developer whose products (e.g., DNA polymerases, nucleases) are used in nucleic acid manufacturing workflows including enzymatic DNA synthesis and mRNA production. Adjacent enabling technology player in Mediphage's value chain rather than a direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mediphage Bioceuticals social profiles
Digital presenceMediphage Bioceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mediphage Bioceuticals leadership team
Management profileNumber of profiles
Profiles9 records
Mediphage Bioceuticals funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mediphage Bioceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mediphage Bioceuticals
What does Mediphage Bioceuticals do?
Mediphage Bioceuticals develops and manufactures msDNA™ (ministring DNA), a linear covalently closed DNA vector produced via in vivo E. coli fermentation, used as drug substance for gene addition, in vivo gene editing, and DNA vaccines, and as premium starting material for ex vivo cell therapy and mRNA, lentiviral, and rAAV vector manufacturing. The company also maintains an internal therapeutic pipeline targeting Hemophilia A, Stargardt Disease, and an undisclosed CNS disorder.
Is Mediphage Bioceuticals a public or private company?
Mediphage Bioceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mediphage Bioceuticals founded?
Mediphage Bioceuticals was founded in 2019. It employs 11 to 50 people.
Where is Mediphage Bioceuticals based?
Mediphage Bioceuticals is headquartered in Toronto, Canada, in the North America region.
How does Mediphage Bioceuticals make money?
Three revenue lines are on record. Technology Licensing and Partnership Agreements are the primary driver. The others are DNA Product Sales and strategic Co-development Revenue.
Who are Mediphage Bioceuticals's main competitors?
Direct peers on record are Aldevron, Touchlight Genetics, VGXI, GenScript and Eurofins Genomics. Broad incumbents are Lonza, Catalent and Charles River Laboratories. Intravacc is listed as an emerging player. Codexis is listed as an others.
Does Mediphage Bioceuticals have an API?
No public API is recorded for Mediphage Bioceuticals.
What industry is Mediphage Bioceuticals in?
Mediphage Bioceuticals's product category is Genetic Medicine / Gene Therapy Technology. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAAAKAE, Plasmid DNA & mRNA Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2836.